Results 191 to 200 of about 321,312 (283)

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM). [PDF]

JMIR Form Res
Talbot A, Delcour B, Gillot L, Arnulf B, Avet Loiseau H, Boccaccio C, Frenzel L, Karlin L, Kraeuter K, Macro M, Mohty M, Perrot A, Touzeau C, Sonntag C, Hulin C, Moreau P, Decaux O.   +16 more
europepmc   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source

Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108. [PDF]

Blood Cancer J
Choi S, Byun JM, Oh SE, Han J, Jung S, Han S, Shin SH, Yahng SA, Jeon YW, Li J, Park SS, Suzuki K, Min CK, Catholic Research Network for Multiple Myeloma.   +13 more
europepmc   +1 more source

Circulating levels of insulin‐like growth factor I (IGF‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study

British Journal of Haematology, EarlyView.
Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified ...
Yolanda Benavente, Sara Hermosa, Nikos Papadimitriou, Alyssa Clay‐Gilmour, Elizabeth E. Brown, Jonathan N. Hofmann, Nathaniel Rothman, Qing Lan, Sonja I. Berndt, Demetrius Albanes, Mark Purdue, Mitchell J. Machiela, Stephen J. Chanock, Parveen Bhatti, Wendy Cozen, Aaron Norman, Susan L. Slager, James R. Cerhan, Vincent Rajkumar, Shaji K. Kumar, Celine M. Vachon, Anne J. Novak, Thomas M. Habermann, Brian K. Link, Gilles Salles, Herve Ghesquieres, Paige M. Bracci, Elizabeth Holly, Rosalie G. Griffin, Michelle A. T. Hildebrandt, Roel C. H. Vermeulen, P. Martijn Kolijn, Henrik Hjalgrim, Karin Ekström Smedby, Harindra Jayasekara, Simon Cheah, Alain Monnereau, Yu Chen, Alan Arslan, Yawei Zhang, Nicola J. Camp, Douglas W. Sborov, Afaf E. G. Osman, Elad Ziv, Immaculata De Vivo, Vijai Joseph, Lauren R. Teras, Alpa V. Patel, Eleanor Kane, Claire M. Vajdic, Adrien Guilloteau, Pierluigi Cocco, Laia Alemany, Juan Sainz, James McKay, Brenda M. Birmann, Delphine Casabonne   +56 more
wiley   +1 more source

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma. [PDF]

Blood Cancer Discov
Ohlstrom DJ, Pilcher WC, Michaud ME, Acharya C, Satpathy S, Gonzalez-Kozlova E, Jayasinghe RG, Ferguson K, Mumme HL, Nanda S, Song Y, Mantrala S, Karagkouni D, Schulman J, Pabustan N, Vieira Dos Santos J, Sherbenou DW, Keats JJ, Gout AM, Foltz S, Lagana A, Kourelis T, Vij R, Dhodapkar MV, Avigan D, Cho HJ, Baughn LB, Nooka AK, Lonial S, Kumar S, Samur MK, Vlachos IS, Ding L, Gnjatic S, Mulligan G, Bhasin MK.   +35 more
europepmc   +1 more source

High‐throughput monoclonal gammopathy community monitoring programme

British Journal of Haematology, EarlyView.
Gaurav Agarwal, Lauren Campbell, Oluremi Carty, Jemma Larham, Elizabeth Knight, Sally Moore, Sarah Gooding, Jaimal Kothari, Joe Browning, Julia Evans, Lisa Ferguson, Ana Vieira, Liam Swanborough, Pamela Roberts, Elizabeth Bateman, Ross Sadler, Karthik Ramasamy   +16 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions. [PDF]

EJHaem
Julian K, Peterson B, Mohyuddin GR.
europepmc   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders. [PDF]

Cell Stem Cell
Shen Y, Benlabiod C, Watson E, Gurashi K, Fower A, Rodriguez-Romera A, Reyat JS, Adnan-Awad S, Hargreaves R, Kemble S, Smith CG, Croft AP, Oppermann U, Welsh A, Murphy L, Murphy E, Moetazedian A, Jooss N, Wong ZC, Rayes J, Mead AJ, Roy A, Gooding S, Psaila B, Khan AO.   +24 more
europepmc   +1 more source